Ranbaxy Violations Include Unsafe Drugs, U.S. Says in Settlement
This article is for subscribers only.
Ranbaxy Laboratories Ltd. made “adulterated, potentially unsafe” medicines that were illegal to sell, U.S. prosecutors said in a proposed settlement with the Indian drugmaker.
Among alleged violations, Ranbaxy failed to adequately separate the production of penicillin and non-penicillin drugs and failed to take adequate steps to prevent contamination of sterile medicines, the U.S. Justice Department said in a 58-page document filed in federal court in Maryland yesterday.